Actively Recruiting
Evaluating Safety and Dosing of 177LuLu-A9-0631 and 225AcAc-A9-0642 With Imaging in GRPR-Positive Solid Tumors
Led by Alpha-9 Oncology USA Inc. · Updated on 2026-09-04
115
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, effectiveness, and organ dosimetry of two investigational drugs, 177LuLu-A9-0631 and 225AcAc-A9-0642, in adults with Gastrin-Releasing Peptide Receptor GRPR expressing locally advanced, unresectable, or metastatic solid tumors. This Phase 1-1b multicenter study aims to establish safe dosing and explore how these drugs work in patients with breast cancer, prostate cancer, colorectal cancer, and other GRPR-positive tumors. The study is sponsored by Alpha-9 Oncology USA Inc. The study has two parts Phase 1 involves gradually increasing doses of the drugs to find the maximum tolerated dose and recommended dose for later studies. Phase 1b expands to more participants to further assess safety, effectiveness, and dosimetry at the determined dose. The investigational drugs, along with diagnostic tests using 68GaGa-A9-6217 and low dose 177LuLu-A9-0631, are given intravenously. Each treatment cycle lasts 28 days, with up to six cycles possible. Participants will be closely monitored for side effects, treatment responses, and radiation doses absorbed by organs and tumors. Evaluations include scans, imaging, laboratory tests, and safety assessments from the first dose through 30 days after the last dose. Objective response rates and absorbed dose estimates are measured regularly up to 12 months after treatment. The entire study period extends through December 2029, with ongoing safety and efficacy follow-up.
CONDITIONS
Brief Title
A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors
Research Team
S
Stephen Hull, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here